8P9W

vitamin D receptor complex with Xe4MeCF3 analog

Summary for 8P9W

• Entry DOI: 10.2210/pdb8p9w/pdb
• Descriptor: Vitamin D3 receptor A, Nuclear receptor coactivator 1, (1~{R},3~{S},5~{Z})-5-[(2~{E})-2-[(1~{S},3~{a}~{S},7~{a}~{S})-1,7~{a}-dimethyl-1-[6,6,6-tris(fluoranyl)-5-oxidanyl-5-(trifluoromethyl)hexa-1,3-diynyl]-2,3,3~{a},5,6,7-hexahydroinden-4-ylidene]ethylidene]-4-methylidene-cyclohexane-1,3-diol, ... (4 entities in total)
• Functional Keywords: nuclear receptor, agonist, ligand binding domain, transcription
• Biological source: Danio rerio (zebrafish); More
• Total number of polymer chains: 2
• Total formula weight: 36353.26

Authors

Belorusova, A.Y.,Rochel, N. (deposition date: 2023-06-06, release date: 2024-06-26, Last modification date: 2024-10-16)

Primary citation

Len-Tayon, K.,Beraud, C.,Fauveau, C.,Belorusova, A.Y.,Chebaro, Y.,Mourino, A.,Massfelder, T.,Chauchereau, A.,Metzger, D.,Rochel, N.,Laverny, G.
A vitamin D-based strategy overcomes chemoresistance in prostate cancer.
Br.J.Pharmacol., 181:4279-4293, 2024

PubMed Abstract: Castration-resistant prostate cancer (CRPC) is a common male malignancy that requires new therapeutic strategies due to acquired resistance to its first-line treatment, docetaxel. The benefits of vitamin D on prostate cancer (PCa) progression have been previously reported. This study aimed to investigate the effects of vitamin D on chemoresistance in CRPC.

PubMed: 38982588
DOI: 10.1111/bph.16492

Experimental method

X-RAY DIFFRACTION (2.9 Å)